Puma Q3 Net Income Falls to $6.0M; Full-Year Profit Outlook Raised to $20-22M
PBYI has more than doubled off its 52-week low of $4.575.
Summary
Puma reported Q3 2026 total revenue of $55.1M versus $54.5M a year ago, with net product revenue of $54.1M up from $51.9M. GAAP net income fell to $6.0M, or $0.11 per diluted share, from $8.8M, or $0.17, a year earlier, as R&D spending rose to $18.3M from $15.9M on alisertib trial activity. The company raised its full-year 2026 net income outlook to $20-22M from $17-20M, but narrowed total revenue guidance to $224-227M from $224-231M and lifted its gross-to-net assumption to 27.5%-28% from 26.5%-27.5%. Royalty revenue took a $2.1M hit from a change in accounting estimate after generic NERLYNX share in China crossed a threshold, and management said some ex-U.S. partner sales slipped from Q3 into Q4. Cash and marketable securities stood at $108.5M with no debt. Updated ALISCA-Breast1 data is due at the San Antonio Breast Cancer Symposium in December 2026.
At the time of this announcement, PBYI was trading at $9.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $504.3M. The 52-week trading range was $4.58 to $11.50. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: BusinessWire.